Methods and compositions using racemic, (R)-, and (S)-fexofenadine in combination with leukotriene inhibitors
Methods and pharmaceutical compositions employing a terfenadine metabolite and a leukotriene inhibitor for the treatment or prevention of inflammation or allergic disorders, such as asthma, or symptoms thereof. Also included are methods and compositions employing a terfenadine metabolite, a leukotriene inhibitor, and a decongestant for the treatment or prevention of inflammation or allergic disorders, such as asthma, or symptoms thereof.
1. A method of treating dermatitis in a human which comprises administering to the human a therapeutically effective amount of racemic fexofenadine, (R)-fexofenadine, (S)-fexofenadine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of zileuton, docebenone, piripost, ICI-D2318, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the amount of racemic fexofenadine, (R)-fexofenadine, (S)-fexofenadine, or a pharmaceutically acceptable salt thereof, is from 0.01 to 500 mg.
3. The method of claim 1 , wherein the amount of the zileuton, docebenone, piripost, or ICI-D2318, or a pharmaceutically acceptable salt thereof, is from 20 mg to 2500 mg.
4. The method of claim 1 , wherein optically pure (R)-fexofenadine, or a pharmaceutically acceptable salt thereof, is administered.
5. The method of claim 1 , wherein optically pure (S)-fexofenadine, or a pharmaceutically acceptable salt thereof, is administered.
6. A method of treating dermatitis in a human which comprises administering to the human a composition, said composition comprising (i) a therapeutically effective amount of racemic fexofenadine, (R)-fexofenadine, (S)-fexofenadine, or a pharmaceutically acceptable salt thereof; (ii) a therapeutically effective amount of MK-591, MK-886, or a pharmaceutically acceptable salt thereof.
7. The method of claim 6 , wherein the amount of racemic fexofenadine, (R)-fexofenadine, (S)-fexofenadine, or a pharmaceutically acceptable salt thereof, is from 0.01 to 500 mg.
8. The method of claim 6 , wherein the amount of the MK-591 or MK-886, or a pharmaceutically acceptable salt thereof, is from 20 mg to 2500 mg.
9. The method of claim 6 , wherein optically pure (R)-fexofenadine, or a pharmaceutically acceptable salt thereof, is administered.
10. The method of claim 6 , wherein optically pure (S)-fexofenadine, or a pharmaceutically acceptable salt thereof, is administered.
11. A method of treating dermatitis in a human which comprises administering to the human a therapeutically effective amount of optically pure (R)-fexofenadine, optically pure (S)-fexofenadine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of zafirlukast, montelukast, pranlukast, sodium 1-(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethynyl)phenyl)-3-(2-(2-hydroxy-2-propyl)phenyl)thio)methyl)cyclopropaneacetate, 1-(((1(R)-(3-(2-(2,3-dichlorothieno[3,2-b]pyridin-5-yl)-(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid, or a pharmaceutically acceptable salt thereof.
12. The method of claim 11 , wherein the amount of racemic fexofenadine, (R)-fexofenadine, (S)-fexofenadine, or a pharmaceutically acceptable salt thereof, is from 0.01 to 500 mg.
13. The method of claim 11 , wherein the amount of the zafirlukast, montelukast, pranlukast, sodium-1-(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethynyl)phenyl)-3-(2-(2-hydroxy-2-propyl)phenyl)thio)methyl)cyclopropaneacetate, or 1-(((1(R)-(3-(2-(2,3-dichlorothieno[3,2-b]pyridin-5-yl)-(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid, or a pharmaceutically acceptable salt thereof, is from 2 mg to 200 mg.
14. The method of claim 11 , wherein optically pure (R)-fexofenadine, or a pharmaceutically acceptable salt thereof, is administered.
15. The method of claim 11 , wherein optically pure (S)-fexofenadine, or a pharmaceutically acceptable salt thereof, is administered.